Eftychia Chatziioannou
Tuebingen, BW 72076, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Insights into RAS-driven melanoma and its therapeutic implications.
Journal: Cancer treatment reviews
Published: November 29, 2025
Metastases in patients with adjuvant therapies: How to proceed?
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 20, 2025
Immune cell senescence drives responsiveness to immunotherapy in melanoma.
Journal: Molecular cancer
Published: July 31, 2025
Genetic susceptibility in early-onset melanoma: An observational Greek cohort study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 29, 2025
Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 14, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 26, 2024
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis.
Journal: Frontiers in immunology
Published: November 08, 2024
Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target.
Journal: International journal of molecular sciences
Published: September 04, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Journal: The British journal of dermatology
Published: July 30, 2024
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.
Journal: ESMO open
Published: April 26, 2024
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 11, 2023
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Journal: American journal of clinical dermatology
Published: March 25, 2023
Last Updated: 09/26/2026